+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 59Years
All Genders
ID05554393

Evaluating Venetoclax Combined with Chemotherapy Versus Standard Treatment for Younger Patients with Intermediate Risk Acute Myeloid Leukemia in a Phase II Randomized Trial

Led by National Cancer Institute (NCI) · Updated on 2026-10-28

153

Participants Needed

187

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating treatment options for younger patients with intermediate risk acute myeloid leukemia AML in this phase II trial. The study compares three different drug combinations cytarabine with daunorubicin cytarabine with daunorubicin plus venetoclax and venetoclax with azacitidine. The goal is to see if adding venetoclax improves the elimination of leukemia cells compared to the usual treatment, by measuring undetectable residual disease after therapy. Participants are randomly assigned to one of three treatment groups. One group receives daunorubicin and cytarabine with venetoclax over 28-day cycles, possibly followed by reinduction therapy based on bone marrow assessments. The second group receives azacitidine combined with venetoclax for two 28-day cycles. The third group receives daunorubicin and cytarabine alone, with potential reinduction treatment. Patients undergo bone marrow aspiration, blood sample collection, and heart function tests before and during the study. During the trial, participants will have regular evaluations including bone marrow tests and blood draws to monitor treatment effects and disease status. Heart function is assessed at screening with echocardiography or a MUGA scan. After completing treatment, patients are followed with visits at 4 weeks, every 3 months for the first year, every 6 months in the second year, and yearly thereafter. Researchers track remission rates, toxicities, survival outcomes, and responses based on genetic features for up to 10 years.

CONDITIONS

Brief Title

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here